• **Name:** John V. Mitsios

• **Current Position:**
Assistant Professor of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY
Director of Point of Care testing, New York Presbyterian/Weill Cornell
Assistant Director of the Central Laboratory, New York Presbyterian/Weill Cornell
Assistant Attending Clinical Chemist, New York Presbyterian/Weill Cornell

•**Country:** United States

• **Educational Background:**

2002-2006	Ph.D. in Chemistry (with Honors), University of Ioannina, Ioannina, Greece
1999-2002	M.Sc. in Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece
1993-1997	B.A. in Chemistry (with Honors), Michigan State University, East Lansing, MI

• **Professional Experiences:**

2007- 2010: **Post-doctoral fellow University of California-San Diego, San Diego, CA**
Scientist working in the laboratory of Prof. Sanford J. Shattil on the project entitled: What is vinculin needed for in platelets? Executed procedures involving in vivo mouse models, in vitro functional assays and molecular biology analysis to observe and analyze the functional importance of Vinculin on platelet physiology. Used the FeCl3 model to study in vivo thrombosis. Isolated and cultured primary megakaryocytes from bone marrow. Used various techniques to study platelet functionality (aggregation, spreading, adhesion, etc).

2012-2014: **Post-doctoral fellow Washington University School of Medicine, St. Louis, MO**
Scientist working in the laboratory of Dr. Charles Eby to evaluate the coagulation properties of plasma dehydrated by matrix chaperone technology.

2012-2014: **Clinical Chemistry Fellow Washington University, St. Louis, MO**
Scientist training in Clinical Chemistry under the supervision of Drs. Mitchell G. Scott and Ann M. Gronowski.

2014-present: **Assistant Professor of Pathology and Laboratory Medicine and Assistant Director of the Central Laboratory and Director of Point-of-Care** at Weill Cornell Medical College/ New York Presbyterian Hospital.

• Professional Organizations

2012-present: American Association for Clinical Chemistry (AACC)
2015-present: International Society of Thrombosis and Hemostasis (ISTH)
2016-present: AACC Hematology/Coagulation Division
(pending approval from Board of Directors). Officer: Chair

• Main Scientific Publications:

Peer Reviewed Manuscripts:

1. Biris N, Abatzis M, **Mitsios JV**, Sakarellos-Daitsiotis M, Sakarellos C, Tsoukatos D, Tselepis AD, Michalis L, Sideris D, Konidou G, Soteriadou K, and Tsikaris V. Mapping the binding domains of the α_{IIb} subunit: A study performed on the activated form of the platelet integrin $\alpha_{IIb}\beta_3$. *Eur J Biochem* 2003;270:3760-3767.

2. **Mitsios JV**, Tambaki AP, Abatzis M, Biris N, Sakarellos-Daitsiotis M, Sakarellos C, Soteriadou K, Goudevenos J, Elisaf M, Tsoukatos D, Tsikaris V and Tselepis AD. Effect of synthetic peptides corresponding to residues 313-332 of the αIIb subunit on platelet activation and fibrinogen binding to αIIbβ3. *Eur J Biochem.* 2004;271:855-862.

3. **Mitsios JV**, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis A. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. *Circulation.* 2004;109:1335-1338.

4. Tsironis LD, **Mitsios JV**, Milionis HJ, Elisaf M, Tselepis AD. Effect of lipoproten (a) on platelet activation induced by platelet-activating factor (PAF): Role of apolipoprotein (a) and endogenous PAF-acetylhydrolase. *Cardiovas Res.* 2004;63:130-138.

5. Tsironis LD, Katsouras CS, Lourida ES, **Mitsios JV**, Goudevenos J, Elisaf M, Tselepis AD. Reduced PAF-acetylhydrolase activity associated with Lp(a) in patients with coronary artery disease. *Atherosclerosis.* 2004;177:193-201.

6. **Mitsios JV**, Papathanasiou AI, Elisaf M, Goudevenos JA, Tselepis AD. The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20 mg/day) for 5 weeks in patients with acute coronary syndromes. *Platelets.* 2005;16:287-92.

7. Kouki A, **Mitsios JV**, Sakarellos-Daitsiotis M, Sakarellos C, Tselepis AD, Tsikaris V, Tsoukatos DC. Highly constrained cyclic (S,S) -CXaaC- peptides as inhibitors of fibrinogen binding to platelets. *J Thromb Haemost.* 2005;3:2324-30.

8. **Mitsios JV**, Vini MP, Stengel D, Ninio E, Tselepis AD. Human Platelets Secrete

the Plasma Type of Platelet-Activating Factor Acetylhydrolase Is Not Associated With Microparticles. *Arterioscler Thromb Vasc Biol.* 2006;26:1902-1903.

9. **Mitsios JV**, Stamos G, Rodis FI, Tsironis LD, Stanica M-R, Sakarellos C, Tsoukatos D, Tsikaris V, and Tselepis AD. Investigation of the role of adjacent amino acids to the 313-320 sequence of the α_{IIb} subunit on platelet activation and fibrinogen binding to $\alpha_{IIb}\beta_3$. *Platelets.* 2006;17:277-282.

10. Prevost N, **Mitsios JV**, Kato H, Burke JE, Dennis EA, Shimizu T, Shattil SJ. Group IVA cytosolic phospholipase A2 (cPLA2α) and integrin αIIbβ3 reinforce each other's functions during αIIbβ3 signaling in platelets. *Blood.* 2009;113:447-57.